Cargando…

PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS

Detalles Bibliográficos
Autores principales:	Dogu, Mehmet Hilmi, Tekgunduz, Ali Irfan Emre, Deveci, Burak, Korkmaz, Gulten, Comert, Melda, Sevindik, Ömür Gökmen, Yokus, Osman, Serin, Istemi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430251/ http://dx.doi.org/10.1097/01.HS9.0000974412.42102.11

Ejemplares similares

Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES
por: Altunok, Oguz, et al.
Publicado: (2023)

PB2400: THE EFFECT OF BONE MARROW CD4/CD8+ RATIO ON RESPONSE TO TREATMENT AND SURVIVAL IN LYMPHOMAS
por: Can Cavdar, Vahit, et al.
Publicado: (2023)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
por: Yokus, Osman, et al.
Publicado: (2023)

PB2245: POLYCYTHEMIA VERA (PV) AND SECONDARY POLYCYTHEMIA (SP): ARE METABOLIC DIFFERENCES JUST THEORIES?
por: Yokus, Osman, et al.
Publicado: (2023)

PB2237: NON-THROMBOTIC INCREASED PORTAL VENOUS PRESSURE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: IS IT JUST A HYPOTHESIS?
por: Yokus, Osman, et al.
Publicado: (2023)

PB2321: THE EFFECT OF PRE-TREATMENT SERUM KINDLIN-3 ON HODGKIN AND NON-HODGKIN LYMPHOMAS: A SINGLE CENTER EXPERIENCE
por: Keskin, Melike, et al.
Publicado: (2023)

PB1752: SAMATYA-PREDICTING SCORE IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): COMBINING CLINICAL FEATURES WITH FLOW CYTOMETRY
por: Cinli, Tahir Alper, et al.
Publicado: (2023)

PB2075: HOW EFFECTIVE ARE LEPTIN GENE POLYMORPHISMS AND METHYLATION DURING THE COURSE OF MULTIPLE MYELOMA (MM)?
por: Serin, Istemi, et al.
Publicado: (2023)

First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS)
por: Sevindik, Omur Gokmen, et al.
Publicado: (2022)

Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019)

To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
por: Sevindik, Omur Gokmen, et al.
Publicado: (2022)

The use of hypomethylating agents in hematologic malignancies: treatment preferences and results
por: Serin, Istemi, et al.
Publicado: (2021)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

PB1865: NPM1-MUT MONITORING DURING GILTERITINIB TREATMENT IDENTIFIES DIFFERENT DYNAMICAL PATTERNS IN RESPONSIVE PATIENTS
por: Sartor, Chiara, et al.
Publicado: (2023)

PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
por: Bouchakor Moussa, Y., et al.
Publicado: (2022)

A case report: paroxysmal nocturnal hemoglobinuria and systemic lupus erythematosus association
por: Serin, Istemi, et al.
Publicado: (2020)

PB1841: A NEW APPROACH IN ACUTE MYELOID LEUKEMIA (AML): SAMATYA-PREDICTING SCORE
por: Serin, I., et al.
Publicado: (2022)

Recurrence of lymphoma with isolated pericardial mass: a case report
por: Serin, Istemi, et al.
Publicado: (2020)

COVID-19 Pneumonia or Hypereosinophilic Syndrome?
por: Serin, Istemi, et al.
Publicado: (2020)

PB2702: POLYPHARMACY IN HEMATOLOGY PRACTISE: A SINGLE CENTER EXPERIENCE
por: Karişmaz, Kadir, et al.
Publicado: (2023)

Secondary Immunodeficiency Frequency in Patients with Chronic Lymphocytic Leukemia: The Relationship with Stage and Treatment
por: Yokus, Osman, et al.
Publicado: (2022)

PB1850: A DOSE FINDING AND EXPANSION OPEN LABEL, MULTICENTER STUDY OF IADADEMSTAT AND GILTERITINIB IN PATIENTS WITH RELAPSE/REFRACTORY ACUTE MYELOID LEUKEMIA WITH MUTATED FLT3: THE FRIDA STUDY
por: Fathi, A., et al.
Publicado: (2022)

Prognostic Role of Lymphocyte/Monocyte Ratio in Chronic Lymphocytic Leukemia
por: Yokus, Osman, et al.
Publicado: (2020)

Iron overload during the treatment of acute leukemia: pretransplant transfusion experience
por: Yokus, Osman, et al.
Publicado: (2021)

PB2449: EFFECT OF MOBILIZATION METHODS ON CD34+ AND TOTAL NUCLEATED CELL COUNT AND THEIR RELATION WITH ENGRAFTMENT IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Beyler, Ozlem, et al.
Publicado: (2023)

Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer
por: Aksoy, Asude, et al.
Publicado: (2017)

A Huge Mass in the Liver: Plasmacytoma
por: Cinli, Tahir Alper, et al.
Publicado: (2022)

Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
por: Yiğit Kaya, Süreyya, et al.
Publicado: (2023)

A Primary Bone Diffuse Large B-Cell Lymphoma with Ocular Adnexal Involvement
por: Eren, Rafet, et al.
Publicado: (2016)

A diffuse large B cell lymphoma emerging with breast cancer relapse
por: Karismaz, Abdulkadir, et al.
Publicado: (2018)

Lateral flow assay (LFA) in the diagnosis of COVID-19-associated pulmonary aspergillosis (CAPA): a single-center experience
por: Serin, Istemi, et al.
Publicado: (2022)

PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
por: Patel, Anand, et al.
Publicado: (2023)

Persistent Polyclonal B-Cell Lymphocytosis with Binucleated Lymphocytes
por: Balık Aydın, Berrin, et al.
Publicado: (2021)

A new approach in acute myeloid leukemia (AML): Samatya-predicting score
por: Serin, Istemi, et al.
Publicado: (2022)

Welcome, 1897
Publicado: (1896)

Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
por: Yildiz, Ismail, et al.
Publicado: (2017)

Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
por: Karakus, Volkan, et al.
Publicado: (2022)

1897: A Retrospect
Publicado: (1898)

Annual Address, 1897
por: Truman, James
Publicado: (1897)

Cannot write session to /tmp/vufind_sessions/sess_n1ljk4mag0amr248ad0bksjfm9